# Hypertriglyceridemia FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/hypertriglyceridemia

> 2 upcoming FDA catalysts in hypertriglyceridemia: REDEMPLO (plozasiran, ARWR) on July 2028 (primary completion); REDEMPLO (plozasiran, ARWR) on Jul to Oct 2028 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 1, 2026 | [REDEMPLO (plozasiran) primary completion](https://sec-api.dev/pdufa/plozasiran) | ARWR | Hypertriglyceridemia | completed | "NCT06347133 (Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-01 (ACTUAL); Lead Sponsor Arrowhead Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06347133)) |
| July 2028 | [REDEMPLO (plozasiran) primary completion](https://sec-api.dev/pdufa/plozasiran) | ARWR | Hypertriglyceridemia | scheduled | "NCT06822790 (Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Arrowhead Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06822790)) |
| Jul to Oct 2028 | [REDEMPLO (plozasiran) topline data readout](https://sec-api.dev/pdufa/plozasiran) | ARWR | Hypertriglyceridemia | scheduled | "NCT06822790 (Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Arrowhead Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06822790)) |

## Drugs

- [REDEMPLO (plozasiran)](https://sec-api.dev/pdufa/plozasiran) (ARWR)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/hypertriglyceridemia.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Hypertriglyceridemia FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/hypertriglyceridemia

```bibtex
@misc{secapidev_indications_hypertriglyceridemia_20261116,
  title        = {Hypertriglyceridemia FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/hypertriglyceridemia}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_hypertriglyceridemia_20261116","title":"Hypertriglyceridemia FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/hypertriglyceridemia","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
